Dr. Brian S. Cornblatt is the Clinic Director and Director of Personalized & Precision Medicine for Quantum Longevity AI, and Chief Scientific and Research Officer of Quantum Longevity AI Health Optimization Clinic. In these roles, Dr. Cornblatt focuses in the clinic on uncovering genetic vulnerabilities to detect root causes of dysfunction and helps the treatment teams develop personalized plans for each client to promote true health promotion.
As Chief Scientific & Research Officer, Dr. Cornblatt focuses on Quantum’s medical and scientific investments, guiding translational research initiatives and assisting with product supporting pre-clinical and clinical trial company strategies. He also helps identify and vet potential new investment targets and modify, as needed, the business strategy of companies whose operations will be assisted by the firm. He also guides parent and portfolio companies with product development plans, with an emphasis on creating additional intellectual property, and accelerating both growth and regulatory approvals.
Dr. Cornblatt is also Chief Medical Officer of AION Biosystems, cofounder and Chief Scientific Officer of International Nutrition Associates (INA) and Integrative Health Solutions (IHS). INA provides clinical trial-backed nutraceuticals to countries throughout Asia and South America as well as novel and high-quality raw materials globally, while IHS provides global distribution services for nutraceuticals. Dr. Cornblatt serves as a Board Member for the Johns Hopkins Colorectal Cancer Center of Excellence, Microbiome Alliance for Disease Prevention, and Longevity AI.
Prior to these roles, Dr. Cornblatt was Chief Medical Officer for BioHarvest Sciences. In this role, Dr. Cornblatt oversaw product development and supported company products through the development of translational research initiatives, including clinical trials. He also supported marketing efforts aimed at informing consumers and healthcare workers about the molecular mechanisms of action of company products. He remains Senior Scientific Consultant for BioHarvest Sciences.
As Director, Clinical Research and Science for Nutramax Laboratories Consumer Care, Inc., Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies (28 total clinical trials over a 13-year period) in support of products, summarized both supporting laboratory and clinical research for healthcare workers and consumers, and developed novel IP and patents (8 patents awarded and 6 provisional patents filed and under review globally).
From 2007–2010 Dr. Cornblatt was the Scientific Director and developer of the Catholic Health Initiatives’ Center for Translational Research (CTR), a combined molecular research laboratory, national biorepository, and diagnostics laboratory. The CTR supported research initiatives throughout CHI’s 42 Oncology centers and worked with the CHI Oncology Network, a clinical trials group that participated in Phase I – Phase IV clinical trials, which Dr. Cornblatt oversaw. In addition, Dr. Cornblatt served on the Catholic Health Institutional Review Board (IRB) as well as the Catholic Health Ventures Fund, where he identified and vetted emerging companies for external investments.
A Johns Hopkins University School of Medicine graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology, Dr. Cornblatt has been involved in medical research since 1990. In academia, Dr. Cornblatt worked on additional translational research endeavors. Dr. Cornblatt’s main research interests are focused on developing novel formulations comprised of natural based phytochemicals, including isothiocyanates, to minimize chronic inflammation and combat the threats of environmental toxicants.
He led development of a novel line of products, Avmacol®, which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Through his efforts, Avmacol has been used in twenty-eight supporting human clinical studies globally. Dr. Cornblatt served on the board of the Susan Cohan Colon Cancer Foundation. His father is now a 29-year survivor of metastatic colorectal cancer, and his mother is a survivor of both colon and uterine cancer. Both have had profound influences on his career.
Dr. Cornblatt is the father of two incredible daughters and, when in the United States, spends his nights and weekends outdoors as much as possible, walking or cycling in the rural counties of western Maryland. Throughout much of 2026 and 2027, Dr. Cornblatt will be in New Providence, Bahamas, directing the newest Functional Medicine Health Optimization Center and spending as much time outside of the clinic on a beach taking in the amazing views.
